“BMS-986165, an Oral, Selective TYK2 Inhibitor, in the Treatment of Moderate to Severe Psoriasis as Assessed by the Static Physician’s Global Assessment (sPGA)/Body Surface Area (BSA) Composite Tool (sPGAxBSA), a Clinically Useful Alternative to PASI” (2020) SKIN The Journal of Cutaneous Medicine, 4(5), p. s29. doi:10.25251/skin.4.supp.29.